Search
Bezitramide
go.drugbank.com/drugs/DB01459ApprovedIllicitWithdrawnAfter cases of fatal overdose in the Netherlands in 2004 the drug was withdrawn from the market. Bezitramide has never been FDA approved and is currently a schedule II drug.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSermorelin
go.drugbank.com/drugs/DB00010ApprovedWithdrawnSermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing
Ipilimumab
go.drugbank.com/drugs/DB06186ApprovedInvestigational[L12126] Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. … Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4).
Categories: Increased T Lymphocyte ActivationSpironolactone
go.drugbank.com/drugs/DB00421ApprovedInvestigational[A11837, A178246] It is indicated to treat several conditions, including heart failure, edema, hyperaldosteronism, and hypertension. … It binds to mineralocorticoid receptors and functions as aldosterone antagonists.[A178192] It promotes sodium and water excretion and potassium retention.
Dithiazanine
go.drugbank.com/drugs/DB11516ApprovedVet approvedWithdrawnDithiazanine iodide has been withdrawn from the market in countries such as France in Italy, but it may remain available in others.[A254427,L44032] … However, its use is severely limited due to its toxicity. Dithiazanine iodide was associated with eight fatal cases of severe acidosis and shock between 1961 and 1964.
Orlistat
go.drugbank.com/drugs/DB01083ApprovedInvestigationalObesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. … In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical intervention is required.
Colestipol
go.drugbank.com/drugs/DB00375Approved[FDA Label, F4555, F4567, L6262] And even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia … secretion of bile acids and lipids in the feces, patients who take complicated medication regimens, experience constipation or biliary obstruction, etc. may not be good candidates for using the agent owing to
Filgotinib
go.drugbank.com/drugs/DB14845ApprovedInvestigational[A189165] Filgotinib is currently reserved for patients who cannot tolerate DMARDs, or who have been unable to achieve remission in response to one or more DMARDs.[L16616] … [A189165] JAK2 and JAK3 play important roles in both immune and hematologic functions; therefore, selectivity for JAK1 aims to improve the safety profile of filgotinib while maintaining clinical efficacy
Abacavir
go.drugbank.com/drugs/DB01048ApprovedInvestigationalIn vivo, abacavir sulfate dissociates to its free base, abacavir. … Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS.
Mixtures: N/ANeisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen
go.drugbank.com/drugs/DB10801ApprovedInvestigationalThe vaccine contains *N. meningitis* serogroup W-135 capsular polysaccharide antigens that are purified and individually conjugated to diphtheria toxoid protein that are extracted from *Corynebacterium … Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria